Methods of detection and removal of rhabdoviruses from cell lines
US-10501500-B2 · Dec 10, 2019 · US
US11286282B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11286282-B2 |
| Application number | US-201916662784-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 24, 2019 |
| Priority date | Oct 3, 2013 |
| Publication date | Mar 29, 2022 |
| Grant date | Mar 29, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure relates to compositions, methods, mixtures, and kits for detecting the presence of, and for removing, a virus from a product produced in an insect cell. The disclosure also relates to proteins, peptides, polypeptides, drug substances, biological products, vaccine antigens, and virus-like particles that are produced in an insect cell and that are free or substantially free of a virus. The disclosure also relates to compositions, methods, assays, and kits for detecting a rhabdovirus in a sample.
Opening claim text (preview).
What is claimed is: 1. A rhabdovirus-free Sf9 or Sf21 insect cell comprising a biological product. 2. The insect cell of claim 1 , wherein the insect cell is free of a nucleotide sequence having at least 70% homology to SEQ ID NO:1. 3. The insect cell of claim 1 , wherein the insect cell is an Sf9 cell. 4. The insect cell of claim 3 , wherein the Sf9 cell is derived from the cell line deposited as ATCC CRL-1711. 5. The insect cell of claim 1 , wherein the biological product is a protein, peptide, drug substance, virus-like particle (VLP), DNA, RNA, virus, or vaccine antigen. 6. The insect cell of claim 1 , wherein the biological product is a recombinant virus for gene therapy. 7. The insect cell of claim 1 , wherein the biological product is a protein or virus-like particle (VLP). 8. The insect cell of claim 1 , wherein the insect cell is free of a nucleotide sequence comprising the sequence according to SEQ ID NO: 1.
Extraction; Separation; Purification · CPC title
Specific hybridization probes · CPC title
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
Methods of production or purification of viral material · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.